Calcified plaque in vessel wall

Calcified plaque in the vessel wall refers to the hard, mineralized deposits that form within the walls of arteries as a result of atherosclerosis or other vascular diseases. These plaques consist of lipids, cholesterol, cell debris, and calcium phosphate crystals, primarily hydroxyapatite, leading to vessel stiffening and narrowing[1][4][5]. Calcified plaques can develop in both the intimal and medial layers of the vessel wall and are highly associated with an increased risk of cardiovascular events such as heart attack and stroke, especially when detected in coronary arteries[1][4]. The formation of these plaques involves complex molecular pathways including inflammation, VSMC (vascular smooth muscle cell) transdifferentiation to an osteogenic phenotype, and signaling cascades such as Wnt/β-catenin, BMPs, and RANKL[2][5]. While the presence of calcified plaque is essential for risk stratification (such as through coronary artery calcium scoring), the plaque itself is not a classical molecular therapeutic target like a receptor or enzyme; rather, its formation and regression are influenced by upstream molecular processes and systemic diseases[3][4]. Therapeutic interventions currently focus on underlying causes and risk factors rather than direct targeting of calcified plaque, though research continues into modulating key pathways involved in its development[3][6]. Note: - “Calcified plaque in vessel wall” is not a standard therapeutic target (e.g., a molecular entity such as a receptor or enzyme) but a complex pathologic lesion or biomarker. Thus, _is_target_ = false and _is_incorrect_ = true for the context of structured molecular target databases, though molecular pathways involved in calcification (e.g., RUNX2, ABCC6) are being actively studied as potential indirect therapeutic targets[3][2].

Other names

Calcified atherosclerotic plaqueVascular calcified plaqueArterial calcified plaqueCoronary artery calcificationVascular calcification

Statins: lower lipid components of plaque, may modestly impact calcification[1] Drugs targeting IGFBP3, ABCC6, ENPP1/PPi axis, DOT1L, ULK3, KLB, AMH: under research for modifying calcification pathways[3]